Antibodies are highly potent therapeutic scaffolds with more than a hundred different
products approved on the market. Successful development of antibody-based drugs …

Therapeutic monoclonal antibodies and their derivatives are key components of clinical
pipelines in the global biopharmaceutical industry. The availability of large datasets of …

Monoclonal antibodies have emerged as key therapeutics. In particular, nanobodies, small,
single-domain antibodies that are naturally expressed in camelids, are rapidly gaining …

In addition to activity, successful biological drugs must exhibit a series of suitable
developability properties, which depend on both protein sequence and buffer composition …

Long-term stability of monoclonal antibodies to be used as biologics is a key aspect in their
development. Therefore, its possible early prediction from accelerated stability studies is of …

Antibody drugs should exhibit not only high-binding affinity for their target antigens but also
favorable physicochemical drug-like properties. Such drug-like biophysical properties are …

Although antibodies have become the fastest-growing class of therapeutics on the market, it
is still challenging to develop them for therapeutic applications, which often require these …

Therapeutic proteins and antibodies are exposed to a variety of interfaces during their
lifecycle, which can compromise their stability. Formulations, including surfactants, must be …

Governments and biopharmaceutical organizations aggressively leveraged expeditious
communication capabilities, decision models, and global strategies to make a COVID‐19 …

Engineered antibody formats, such as antibody fragments and bispecifics, have the potential
to offer improved therapeutic efficacy compared to traditional full-length monoclonal …